Barclays resumed coverage on Moderna with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for MRNA
Across the 14 sessions after earlier MRNA headlines, the stock closed higher 7 times and lower 7 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MRNA | SPY |
|---|---|---|---|
| Jan 26, 2026 | Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026 | -1.5% | +0.5% |
| Jan 12, 2026 | Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference | -1.3% | +0.2% |
| Jan 7, 2026 | UBS resumed coverage on Moderna with a new price target | +0.6% | -0.3% |
| Jan 5, 2026 | Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine | +4.2% | +0.7% |
| Dec 18, 2025 | CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate | +1.4% | +0.8% |
| Dec 17, 2025 | Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference | +2.1% | -1.1% |
Quantisnow market dataNASDAQ
MRNA
Moderna Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2018
Get push alerts for MRNA
Full MRNA profile on Quantisnow Follow MRNA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time